Juan P Cata1, Mark Zafereo2, John Villarreal3, Bryant D Unruh2, Angela Truong3, Dam-Thuy Truong3, Lei Feng4, Vijaya Gottumukkala3. 1. Department of Anaesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Centre, Houston, TX, USA; Anesthesia and Surgical Oncology Research Group. Houston, TX, USA. Electronic address: jcata@mdanderson.org. 2. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Centre, Houston, TX, USA. 3. Department of Anaesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Centre, Houston, TX, USA. 4. Department of Biostatistics, The University of Texas MD Anderson Cancer Centre, Houston, TX, USA.
Abstract
STUDY OBJECTIVE: To assess whether the use of intraoperative opioids is associated with poor recurrence-free survival (RFS) and overall survival (OS) after lung cancer surgery. DESIGN: Retrospective study. SETTING: Academic hospital. SUBJECTS: Patients with laryngeal primary or recurrent laryngeal squamous cell carcinoma who had surgery. INTERVENTIONS: Intravenous opioids (remifentanil, fentanyl, sufentanil, and hydromorphone). MEASUREMENTS: Univariate and multicovariate Cox proportional hazards models were applied to assess the effects of covariates of interest on OS and RFS. MAIN RESULTS: A total of 195 patients were included. All received opioids intraoperatively. The multivariate analysis demonstrated that age (hazard ratio [HR], 1.03; P = .005), negative margin status (HR, 0.163; P = .001], postoperative chemotherapy (HR, 7.38; P < .001), and concurrent chemotherapy and radiation (HR, 3.11; P < .001) treatment and fentanyl equivalent use (HR, 1.001; P = .02) were all predictor factors for 3- and 5-year RFS. The same variables were predictor factors for OS (age: HR, 1.03 [P = .003]; negative margin status: HR, 0.14 [P = .001]; postoperative chemotherapy: HR, 4 [P < .0001]; and fentanyl equivalent use: HR, 1.001 [P = .02]). CONCLUSIONS: Our study demonstrates a very weak association between the use of intraoperative opioids and cancer recurrence after laryngeal squamous cell carcinoma surgery.
STUDY OBJECTIVE: To assess whether the use of intraoperative opioids is associated with poor recurrence-free survival (RFS) and overall survival (OS) after lung cancer surgery. DESIGN: Retrospective study. SETTING: Academic hospital. SUBJECTS:Patients with laryngeal primary or recurrent laryngeal squamous cell carcinoma who had surgery. INTERVENTIONS: Intravenous opioids (remifentanil, fentanyl, sufentanil, and hydromorphone). MEASUREMENTS: Univariate and multicovariate Cox proportional hazards models were applied to assess the effects of covariates of interest on OS and RFS. MAIN RESULTS: A total of 195 patients were included. All received opioids intraoperatively. The multivariate analysis demonstrated that age (hazard ratio [HR], 1.03; P = .005), negative margin status (HR, 0.163; P = .001], postoperative chemotherapy (HR, 7.38; P < .001), and concurrent chemotherapy and radiation (HR, 3.11; P < .001) treatment and fentanyl equivalent use (HR, 1.001; P = .02) were all predictor factors for 3- and 5-year RFS. The same variables were predictor factors for OS (age: HR, 1.03 [P = .003]; negative margin status: HR, 0.14 [P = .001]; postoperative chemotherapy: HR, 4 [P < .0001]; and fentanyl equivalent use: HR, 1.001 [P = .02]). CONCLUSIONS: Our study demonstrates a very weak association between the use of intraoperative opioids and cancer recurrence after laryngeal squamous cell carcinoma surgery.
Authors: Huaising C Ko; Mandira N Mehra; Adam R Burr; Aaron M Wieland; Randal J Kimple; Gregory K Hartig; Paul M Harari; Matthew E Witek Journal: J Pain Manag Date: 2020
Authors: Jonathan B Yuval; Jasme Lee; Fan Wu; Hannah M Thompson; Floris S Verheij; Hersh V Gupta; Takeshi Irie; Joseph R Scarpa; Patrick J McCormick; J Joshua Smith; Jinru Shia; Martin R Weiser; Francisco Sánchez-Vega; Kay See Tan; Gregory W Fischer; Julio Garcia-Aguilar; Joshua S Mincer Journal: Br J Anaesth Date: 2022-06-17 Impact factor: 11.719
Authors: Upasana Banerjee; Katherine Hagan; Shreyas Bhavsar; Roxana Grasu; Anh Dang; Ian E McCutcheon; Miguel Suarez; Vijaya Gottumukkala; Juan P Cata Journal: J Anaesthesiol Clin Pharmacol Date: 2018 Oct-Dec
Authors: Sabrina Tripolt; Heidi A Neubauer; Vanessa M Knab; Dominik P Elmer; Fritz Aberger; Richard Moriggl; Daniela A Fux Journal: Neoplasia Date: 2021-01-16 Impact factor: 5.715
Authors: James G Connolly; Kay See Tan; Brooke Mastrogiacomo; Joseph Dycoco; Raul Caso; Gregory D Jones; Patrick J McCormick; Francisco Sanchez-Vega; Takeshi Irie; Joseph R Scarpa; Hersh V Gupta; Prasad S Adusumilli; Gaetano Rocco; James M Isbell; Matthew J Bott; Gregory W Fischer; David R Jones; Joshua S Mincer Journal: Br J Anaesth Date: 2021-07 Impact factor: 11.719